Biovica International
19.11.2021 16:17:02 CET | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results - i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
"The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results," said Anders Rylander, CEO of Biovica.
The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.
Contact:
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.
Attachments
Biovica's DiviTum®TKa in three studies at SABCS 2021
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673809/Biovicas-DiviTumRTKa-in-Three-Studies-at-SABCS-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
Karbon-X (OTCQB:KARX) Accelerates High-Margin Transformation in Q1 FY2027: Gross Margin Expands to 32%, Operating Cash Burn Drops 55%, and Deferred Revenue Reaches $4.3 Million22.10.2026 13:45:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced its financial and operational results for the first quarter of fiscal 2027 (ended August 31, 2026), following the filing of its Quarterly Report on Form 10-Q. The quarter was highlighted by a significant expansion in gross margin to 32%, a 55% reduction in net operating cash use, and continued momentum across international project development and advisory engagements. Through disciplined execution, Karbon-X has shifted its commercial mix toward higher-margin, value-added environmental consulting and project commercialization, strengthening its operational foundation for sustainable, long-term growth. First Quarter Fiscal 2027 HighlightsSubstantial Gross Margin Expansion: Gross margin rose to 32%, compared with 0.8% in the prior-year period, reflecting a higher-margin revenue mix centered on technical advisory an
Chervon Appoints Stephen Sarnocinski to President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global21.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 21, 2026 / Stephen (Sarno) Sarnocinski is named President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global, effective October 20, 2026, reporting to Joe Galli, CEO. Sarnocinski brings 21+ years of extraordinary experience, performance and leadership to Chervon. He is a high-potential senior executive with an exciting future ahead at Chervon. Sarno will now assume a new role at Chervon focused on pioneering and developing the OPE Commercial Landscaper User Vertical. Sarno was most recently a Senior Vice President - Job Site Solutions for TTI/Milwaukee, leading the Utility, Energy, Communications and Mining Verticals. Over the past 10 years he has held increasingly responsible JSS positions in the Eastern USA. Before his JSS role, he was responsible for Milwaukee East Coast Service Operations. He started his TTI/Milwaukee career rising through a series of store coverage and territory management positions. Before
DataTracks Launches Nova, Filing Software that Takes UK Micro-Entities Through HMRC and Companies House on One Set of Figures21.10.2026 15:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 21, 2026 / DataTracks, the regulatory reporting software and services provider, has launched DataTracks Nova, software that prepares a UK micro-entity's accounts and Corporation Tax return from a single set of figures, produces the iXBRL that HMRC requires now and Companies House will require from 1 April 2028, and files the CT600 with HMRC. Companies House accounts filing runs from the same data in the same product. Until 31 March 2026, many smaller UK companies with straightforward affairs had a free way to do this themselves. CATO (Company Accounts and Tax Online) was a free HMRC online service, run jointly with Companies House, that let a company prepare and submit its own Corporation Tax return and accounts through a simple web form, with no software to buy and no accountant needed. It was only open to companies filing without an agent. HMRC closed it on 31 March 2026. Since 1 April 2026, companies have generally had to use commercial softwar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom